Data · Tennessee Clinical Trials · ClinicalTrials.gov data of November 4, 2026
1,988 clinical trials are recruiting at Tennessee sites on ClinicalTrials.gov, as of November 4, 2026. That is 3.1% of the 64,624 recruiting studies registered anywhere. 1,306 recruit in Nashville and 445 in Memphis; 839 (42%) study cancer, and industry is the lead sponsor on 1,242. Source: US National Library of Medicine, ClinicalTrials.gov.
What it means
By city: Nashville 1,306, Memphis 445, Knoxville 232, Chattanooga 126. The sites named on the most trials are Vanderbilt University Medical Center, St. Jude Children's Research Hospital, SCRI Oncology Partners. Cancer is the largest disease area, with 839 recruiting trials. 547 recruiting trials are phase 3 or phase 2/3, the late-stage studies that feed new approvals; 468 are early phase.
Lead sponsors by type: Industry 1,242; Academic, hospital or other 591; Research network 78; NIH 62; Other federal 14; Not stated 1. For a health system, an industry-sponsored trial means a contract, a budget and a coordinator workload. For a vendor, it means site selection, eConsent, EHR-to-EDC data flow and patient matching are live problems in this state, not theory.
| Lead sponsor | Trials |
|---|---|
| Vanderbilt University Medical Center | 106 |
| St. Jude Children's Research Hospital | 93 |
| AstraZeneca | 62 |
| National Cancer Institute (NCI) | 48 |
| Merck Sharp & Dohme LLC | 41 |
| Eli Lilly and Company | 35 |
| Pfizer | 34 |
| Janssen Research & Development, LLC | 31 |
| AbbVie | 30 |
| Vanderbilt-Ingram Cancer Center | 30 |
| Children's Oncology Group | 26 |
| Bristol-Myers Squibb | 24 |
Sites
Facility names are as each sponsor typed them, so one institution can appear under several names (for example Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center). Some sponsors list a generic "Research Site".
| Facility | Trials |
|---|---|
| Vanderbilt University Medical Center | 331 |
| St. Jude Children's Research Hospital | 122 |
| SCRI Oncology Partners | 120 |
| Vanderbilt University/Ingram Cancer Center | 94 |
| Research Site | 74 |
| Sarah Cannon Research Institute | 69 |
| Tennessee Oncology | 61 |
| Baptist Memorial Hospital and Cancer Center-Memphis | 51 |
| Vanderbilt University | 45 |
| Baptist Memorial Hospital and Cancer Center-Collierville | 42 |
| Vanderbilt-Ingram Cancer Center | 37 |
| University of Tennessee Medical Center | 29 |
32 studies of any status with a Tennessee site whose title, summary, keywords or interventions describe artificial intelligence or machine learning; 12 are recruiting. Newest start date first.
| Study | Title | Status | Lead sponsor |
|---|---|---|---|
| NCT07217808 | Precision-Medicine Diagnostic Support in Hospitalized Veterans With Acute Kidney Injury | Not yet recruiting | VA Office of Research and Development |
| NCT07768670 | AI-Based Personalized Exercise Prescription Through Mobile Health on Physical Activity and Health Outcomes in Older Adults: A Feasibility Study | Recruiting | The University of Tennessee, Knoxville |
| NCT07775976 | Cor360: Clinician-Facing Broad-Spectrum Cardiac Phenotyping and Risk Assessment Using COR® Wearable ECG to Inform Outcomes-Oriented Care Pathways | Enrolling by invitation | Peerbridge Health, Inc |
| NCT07514819 | Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma | Recruiting | St. Jude Children's Research Hospital |
| NCT07690436 | Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM | Recruiting | AstraZeneca |
| NCT07207993 | Evaluating Health Outcomes of AI-Based Fitness Wearables and App Programs in Older Adults Living Alone With Cognitive Decline | Recruiting | The University of Tennessee, Knoxville |
| NCT07565480 | Collection of Training Data for LuminX Probe AI Models | Active not recruiting | LuminX |
| NCT07355894 | Health Enhanced Artery Risk Tracking With Widespread Implementation and Screening Effort in ASCVD (HEARTWISE-ASCVD) | Not yet recruiting | Stanford University |
| NCT07144319 | Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy | Recruiting | Photocure |
| NCT07333547 | Registry Study for the Evaluation of High-risk Cardiac Patients by WILLEM AI-based ECG Platform | Recruiting | Idoven 1903 S.L. |
| NCT06939803 | AI-driven Clinical Decision Support to Reduce Hospital-Acquired Venous Thromboembolism: Study Protocol for the VTE-AI Randomized Trial. | Recruiting | Vanderbilt University Medical Center |
| NCT06911632 | Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary H | Recruiting | Tempus AI |
| NCT07853703 | A Study of Fresh Produce and AI-Enabled Nutrition Support in Adults With Diabetes in Rural Appalachia | Completed | The University of Tennessee, Knoxville |
| NCT07674758 | Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials | Recruiting | Vanderbilt University Medical Center |
| NCT06638398 | Biomarker Platform (Virtual Nodule Clinic) for the Management of Indeterminate Pulmonary Nodules | Active not recruiting | Vanderbilt-Ingram Cancer Center |
| NCT06285812 | Otitis Treatment With OtoSight™ - Modification of Antibiotic Treatment Intervention in Children | Active not recruiting | PhotoniCare, Inc. |
| NCT06521372 | The Aim of This Study is to Determine if Oocyte Sorting for Group Culture Using an Artificial Intelligence Image Analysis Tool (MagentaTM) Increases the Usable | Recruiting | Ovation Fertility |
| NCT06122077 | Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening | Recruiting | Freenome Holdings Inc. |
| NCT06751576 | Retrospective Clinical Trial Comparing Radiologists' Diagnosis Accuracy in Lung Cancer Screening Population With and Without the Help of an AI/ML Tech-based SaM | Completed | Median Technologies |
| NCT06576232 | Standalone Observational Study Assessing the Performance of an AI/ML Tech-based SaMD on Chest LDCT Images (REALITY) | Completed | Median Technologies |
| NCT05312437 | Clinical Decision Support to Prevent Suicide | Completed | Vanderbilt University Medical Center |
| NCT05606575 | A Study of Detection of Paroxysmal Events Utilizing Computer Vision and Machine Learning - Nelli | Completed | Neuro Event Labs Inc. |
| NCT05214105 | The Predictive Capacity of Machine Learning Models for Progressive Kidney Disease in Individuals With Sickle Cell Anemia | Unknown | University of Tennessee |
| NCT05254834 | The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening | Completed | Freenome Holdings Inc. |
| NCT05113927 | Wide Field OCT + AI for Positive Margin Rates in Breast Conservation Surgery. | Completed | Perimeter Medical Imaging |
| NCT04906135 | Auditory Neural Function in Implanted Patients With Usher Syndrome | Completed | Ohio State University |
| NCT04608617 | SYNCHRONISE: LVO Triage Timing and Outcome Study | Completed | Viz.ai, Inc. |
| NCT04191330 | Artificial Intelligence Mobile Health Trial Of A Digital Platform To Optimize GDMT Using Wearable Sensors | Unknown | Biofourmis Inc. |
| NCT04113733 | Combinatorial Single Cell Strategies for a Crohn's Disease Gut Cell Atlas | Active not recruiting | Vanderbilt University Medical Center |
| NCT03688906 | AI-EMERGE: Development and Validation of a Multi-analyte, Blood-based Colorectal Cancer Screening Test | Completed | Freenome Holdings Inc. |
| NCT03452774 | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | Recruiting | Massive Bio, Inc. |
| NCT03304106 | Clinical Investigation of New CI Delivery Models in an Adult Nucleus CI Population | Completed | Cochlear |
650 most recent of 1,988 recruiting trials, by start date
| Study | Title | Lead sponsor | Phase | Tennessee cities |
|---|---|---|---|---|
| NCT07621614 | A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information | Children's Oncology Group | Phase 2 | Knoxville, Memphis |
| NCT07578116 | Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis | SWOG Cancer Research Network | Phase 3 | Collierville, Memphis |
| NCT07757802 | Phase 1 Study of CH505 HIV Vaccine Nanoparticles and mRNA Boosters in Healthy Adults | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | Nashville |
| NCT07293689 | PREcision MEDicine In Achalasia (PREMEDIA) - Cohort | Northwestern University | Observational | Nashville |
| NCT07884474 | Feasibility and Acceptability of Remote Saliva Collection | St. Jude Children's Research Hospital | Observational | Memphis |
| NCT07846683 | A Study to Assess the Efficacy and Safety of Subcutaneous Induction Therapy With Afimkibart in Participants With Moderately to Severely Active Ulcerative Coliti | Hoffmann-La Roche | Phase 3 | Cordova |
| NCT07908316 | Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Gluca | Amgen | Phase 1 | Knoxville |
| NCT07834710 | Using Bioimpedance Analysis to Monitor Fluid Status in Children | St. Jude Children's Research Hospital | Observational | Memphis |
| NCT07805278 | A Registry of Cases of Spinal Muscular Atrophy | St. Jude Children's Research Hospital | Observational | Memphis |
| NCT07585136 | Stem Cell Mobilization and Apheresis for Life-threatening Blood Disorders | St. Jude Children's Research Hospital | Phase 1 | Memphis |
| NCT07602166 | Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans | Vanderbilt University Medical Center | Phase 2 | Nashville |
| NCT07903415 | A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors. | Pfizer | Phase 1 | Nashville |
| NCT07851103 | A Study to Test Different Doses of BI 3968621 When Given Alone or With Ezabenlimab in Patients With Advanced Cancer | Boehringer Ingelheim | Phase 1 | Nashville |
| NCT07824349 | JUR-003 in Adult Patients With Metastatic Prostate Cancer | Juri Biosciences, Inc. | Phase 1 | Nashville |
| NCT07224711 | The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery | Vanderbilt University Medical Center | Phase 4 | Nashville |
| NCT07775495 | Observational Study of Decentralized Urine Optical Interaction Patterns Associated With Environmental Microplastic and Nanoplastic Exposure | Ecotera Health LLC | Observational | Nashville |
| NCT07753850 | A Study of SL-325 in Crohn's Disease Patients | Shattuck Labs, Inc. | Phase 2 | Nashville |
| NCT07801495 | A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis | Novartis Pharmaceuticals | Phase 2 | Memphis |
| NCT07578649 | Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent | Pfizer | Phase 3 | Nashville |
| NCT07293247 | A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment | Alliance for Clinical Trials in Oncology | Phase 2 | Collierville, Memphis |
| NCT07651514 | The Effect of a Daily Magnesium and Melatonin Supplement on Sleep Quality in People With Nighttime Leg Cramps | StudySetGo | Device or behavioral (no phase) | Nashville |
| NCT07863635 | A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations | ModernaTX, Inc. | Phase 4 | Hendersonville |
| NCT07848191 | Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis | Madrigal Pharmaceuticals, Inc. | Phase 4 | Chattanooga |
| NCT07257419 | CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ | St. Jude Children's Research Hospital | Phase 1 | Memphis |
| NCT06965504 | INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery | Abiomed Inc. | Device or behavioral (no phase) | Nashville |
| NCT07897370 | Cardiac Arrest - Ultrasound Detection of Occult Perfusion | University of Massachusetts, Worcester | Observational | Nashville |
| NCT07843940 | A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35) | Boehringer Ingelheim | Phase 1/2 | Nashville |
| NCT07841977 | Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis | Gilead Sciences | Phase 2 | Johnson City |
| NCT07768670 | AI-Based Personalized Exercise Prescription Through Mobile Health on Physical Activity and Health Outcomes in Older Adults: A Feasibility Study | The University of Tennessee, Knoxville | Device or behavioral (no phase) | Knoxville |
| NCT07637942 | Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | Phase 4 | Memphis |
| NCT07011628 | Transition to Ambulatory Bariatric Surgery (TABS) Trial | Vanderbilt University Medical Center | Device or behavioral (no phase) | Nashville |
| NCT07863193 | Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA) | Sagimet Biosciences Inc. | Phase 3 | Murfreesboro, Nashville |
| NCT07760961 | Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia | Vogenx, Inc. | Phase 2 | Nashville |
| NCT07741643 | Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Ce | Vanderbilt-Ingram Cancer Center | Phase 1 | Nashville |
| NCT07672769 | Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes | Faron Pharmaceuticals Ltd | Phase 2 | Nashville |
| NCT07592299 | To Establish the Safety and Effectiveness of the ALPFA GRAIL PFA System for Treating Symptomatic Benign Prostate Hyperplasia (BPH) Also Known as an Enlarged Pro | ALPFA Medical | Device or behavioral (no phase) | Germantown |
| NCT07559175 | A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency. | Aimmune Nestlé Health Science US R&D, LLC | Phase 2 | Nashville |
| NCT07516301 | Feasibility of Incorporating a Standardized Substance Use Measure With Linked-Brief Intervention Into Routine Psychosocial Care of Adult Childhood Cancer Surviv | St. Jude Children's Research Hospital | Device or behavioral (no phase) | Memphis |
| NCT07843498 | A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity | Hoffmann-La Roche | Phase 3 | Nashville |
| NCT07808151 | Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer | Solstice Oncology, Inc. | Phase 2 | Nashville |
| NCT07741565 | Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC) | Vanderbilt-Ingram Cancer Center | Early phase 1 | Nashville |
| NCT07531043 | Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in Adults | Alcon Research | Phase 3 | Smyrna |
| NCT07520006 | Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies | Nurix Therapeutics, Inc. | Phase 1/2 | Nashville |
| NCT07778498 | A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors. | Phrontline Biopharma | Phase 1/2 | Nashville |
| NCT07768189 | A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma | Corbus Pharmaceuticals Inc. | Phase 3 | Knoxville, Nashville |
| NCT07441278 | A Clinical Trial of NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) | NS Pharma, Inc. | Phase 2 | Knoxville |
| NCT06917911 | Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute M | National Cancer Institute (NCI) | Phase 2 | Collierville, Memphis |
| NCT07578363 | An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in Adults | Alcon Research | Phase 3 | Memphis |
| NCT07817875 | Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have O | Eli Lilly and Company | Phase 3 | Nashville |
| NCT07763210 | Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma | Vanderbilt-Ingram Cancer Center | Phase 2 | Nashville |
| NCT07718581 | HMPL-A830 in Solid Tumors | Hutchmed | Phase 1/2 | Nashville |
| NCT07700979 | Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2- | Akeso | Phase 3 | Nashville |
| NCT06956014 | Efficacy and Safety of VER-01 in the Treatment of Participants With Chronic Painful Lumbosacral Radiculopathy | Vertanical GmbH | Phase 3 | Knoxville |
| NCT07859852 | Evaluation of Diagnostic Accuracy and Clinical Performance of the UllCORE Bloodstream Infection (BSI) Test | Deepull Diagnostics S.L. | Observational | Nashville |
| NCT07819435 | Phase 2/3 Efficacy and Safety of PP405 in Adult Males | Pelage Pharmaceuticals, Inc. | Phase 2/3 | Knoxville, Murfreesboro, Smyrna |
| NCT07748988 | Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell Carcinoma | Vanderbilt-Ingram Cancer Center | Phase 1 | Nashville |
| NCT07611435 | Beginning to Assess an Appropriate CONtrol for Oral Food Challenges in Alpha-Gal Syndrome (CoFAR-13) - BeACON4AG | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | Nashville |
| NCT07594392 | Clinical Assessment and Targeted Imaging to Characterize High-Risk Atherosclerotic Cardiovascular Disease of Survivors in SJLIFE | St. Jude Children's Research Hospital | Observational | Memphis |
| NCT07867080 | A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME). | 4D Molecular Therapeutics | Phase 3 | Nashville |
| NCT07683754 | T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd | Daiichi Sankyo | Phase 3 | Nashville |
| NCT07828860 | Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa | Corvus Pharmaceuticals, Inc. | Phase 1 | Nashville |
| NCT07701941 | A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unres | Daiichi Sankyo | Phase 1/2 | Memphis, Nashville |
| NCT07832292 | A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer | Janssen Research & Development, LLC | Phase 2 | Germantown |
| NCT07817251 | Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema | Novo Nordisk A/S | Phase 3 | Nashville |
| NCT07510048 | Combatting HIV Or Other STIs Early (CHOOSE) | Westat | Device or behavioral (no phase) | Memphis |
| NCT07766499 | A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU) | Calixis Inc. | Phase 2 | Smyrna |
| NCT07711002 | Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progress | AstraZeneca | Phase 3 | Nashville |
| NCT07531498 | Muscle Aging Phenotypes in Childhood Cancer Survivors | St. Jude Children's Research Hospital | Observational | Memphis |
| NCT07606365 | A Study in Adults With Geographic Atrophy | Sitala Bio LTD | Phase 2 | Nashville |
| NCT07815665 | A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma | Summit Therapeutics | Phase 2/3 | Nashville |
| NCT07813637 | Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC | Janux Therapeutics | Phase 1 | Nashville |
| NCT07788521 | Comparison of ACUVUE® OASYS MAX 1-Day Multifocal and DAILIES® AquaComfort Plus® Multifocal | Johnson & Johnson Vision Care, Inc. | Device or behavioral (no phase) | Memphis |
| NCT07623161 | A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib | Takeda | Phase 3 | Nashville |
| NCT07619118 | A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia | AstraZeneca | Phase 3 | Bristol |
| NCT07680790 | Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based C | Bristol-Myers Squibb | Phase 3 | Memphis |
| NCT07623200 | A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia | Incyte Corporation | Phase 3 | Nashville |
| NCT07687485 | Tricuspid Regurgitation Treatment With LAPLACE Transcatheter Tricuspid Valve Replacement System | Laplace Interventional, Inc | Device or behavioral (no phase) | Kingsport |
| NCT07805707 | A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age | GlaxoSmithKline | Phase 3 | Knoxville |
| NCT07609719 | A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy | Genentech, Inc. | Phase 4 | Cordova |
| NCT07637578 | A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma | SCRI Development Innovations, LLC | Phase 2 | Nashville |
| NCT07624305 | A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD) | AstraZeneca | Phase 3 | Chattanooga |
| NCT07140939 | A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat | Caliway Biopharmaceuticals Co., Ltd. | Phase 3 | Nashville |
| NCT06899178 | Atomoxetine in Melanocortin Obesity Syndrome | Icahn School of Medicine at Mount Sinai | Phase 2 | Nashville |
| NCT07849231 | A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms | Damora Therapeutics | Phase 1 | Nashville |
| NCT07804615 | A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Th | Vima Therapeutics | Phase 2 | Memphis |
| NCT07804186 | Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma | IDEAYA Biosciences | Phase 3 | Nashville |
| NCT07794670 | Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease | NewAmsterdam Pharma | Phase 2 | Nashville |
| NCT07766005 | A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial) | Spyre Therapeutics, Inc. | Phase 2 | Nashville, Smyrna |
| NCT07735533 | A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies | Umoja Biopharma | Phase 1/2 | Nashville |
| NCT07686081 | Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis | Vanda Pharmaceuticals | Phase 3 | Nashville |
| NCT07616154 | Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease | St. Jude Children's Research Hospital | Phase 2 | Memphis |
| NCT07594119 | Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures | Rapport Therapeutics Inc. | Phase 3 | Nashville |
| NCT07332182 | MaioRegen Prime Study for the Treatment of Deep Osteochondral Lesion of the Knee | Fin-Ceramica Faenza Spa | Device or behavioral (no phase) | Jackson |
| NCT07245420 | Evaluation Of Cardiovascular Health Outcomes Among Survivors 2 | St. Jude Children's Research Hospital | Device or behavioral (no phase) | Memphis |
| NCT07743463 | A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities | Ascletis Pharma (China) Co., Limited | Phase 3 | Memphis |
| NCT07845487 | A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis | Palisade Bio | Phase 2 | Cordova |
| NCT07743450 | A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes | Ascletis Pharma (China) Co., Limited | Phase 3 | Memphis |
| NCT07766655 | Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT) | Axsome Therapeutics, Inc. | Phase 3 | Knoxville, Memphis, Nashville |
| NCT07705555 | A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004) | Merck Sharp & Dohme LLC | Phase 3 | Johnson City, Knoxville |
| NCT07794579 | A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity | Eli Lilly and Company | Phase 3 | Knoxville, Nashville |
| NCT07771465 | A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy | Kardigan, Inc. | Phase 3 | Nashville |
| NCT07729462 | A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine | Pfizer | Phase 3 | Memphis |
| NCT07797335 | AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes a | Novo Nordisk A/S | Phase 3 | Bristol, Knoxville, Nashville |
| NCT07783425 | A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema | Pfizer | Phase 3 | Memphis |
| NCT07776509 | A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity | AstraZeneca | Phase 3 | Franklin |
| NCT07754461 | A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar | Boehringer Ingelheim | Phase 3 | Chattanooga, Memphis |
| NCT07737743 | A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease | Novartis Pharmaceuticals | Phase 2 | Memphis |
| NCT07783542 | ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa | Oruka Therapeutics, Inc. | Phase 2 | Smyrna |
| NCT07753993 | A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease. | AstraZeneca | Phase 3 | Knoxville, Morristown |
| NCT07428993 | Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma | St. Jude Children's Research Hospital | Phase 2 | Memphis |
| NCT07784270 | A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight | AstraZeneca | Phase 3 | Franklin, Jackson, Knoxville |
| NCT07772921 | A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma | Pfizer | Phase 3 | Smyrna |
| NCT07514819 | Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma | St. Jude Children's Research Hospital | Device or behavioral (no phase) | Memphis |
| NCT07279467 | Study of Oral Food Challenge Biomarkers (SAFER) | National Institute of Allergy and Infectious Diseases (NIAID) | Observational | Nashville |
| NCT07784725 | A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus | AstraZeneca | Phase 3 | Kingsport, Memphis |
| NCT07745361 | Study of Oral MRT-2359 With Apalutamide in Prostate Cancer | Monte Rosa Therapeutics, Inc | Phase 2 | Nashville |
| NCT07022678 | Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia | Children's Oncology Group | Phase 3 | Knoxville, Nashville |
| NCT07774455 | Pacritinib Effectiveness in Real-world Settings | Swedish Orphan Biovitrum | Observational | Nashville |
| NCT07619131 | A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients. | AstraZeneca | Phase 3 | Knoxville |
| NCT07837973 | Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss | Alveus Therapeutics, Inc. | Phase 2 | Nashville |
| NCT07626411 | Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation | Regeneron Pharmaceuticals | Phase 3 | Tullahoma |
| NCT07391774 | Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic S | National Cancer Institute (NCI) | Phase 3 | Collierville, Memphis |
| NCT07767903 | A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 | Memphis |
| NCT07498335 | Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN | Novartis Pharmaceuticals | Phase 3 | Memphis |
| NCT07752979 | Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities | AbbVie | Phase 2 | Bristol, Knoxville, Nashville |
| NCT07282613 | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes | Novo Nordisk A/S | Phase 3 | Memphis |
| NCT07231380 | A Comparison of Cyclic Manual Direct Aspiration Thrombectomy (Plunger Technique) vs. Static Manual Direct Aspiration Thrombectomy for Treatment of Acute Large V | Vanderbilt University Medical Center | Device or behavioral (no phase) | Nashville |
| NCT07779408 | Study to Assess Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Yea | Sanofi | Phase 1/2 | Knoxville |
| NCT07723248 | A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas- | ORIC Pharmaceuticals | Phase 3 | Nashville |
| NCT07674654 | A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine | TriGemX Bio, Inc. | Phase 3 | Chattanooga, Nashville |
| NCT07516093 | Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL | Nurix Therapeutics, Inc. | Phase 3 | Nashville |
| NCT07335523 | Determine the Prevalence of Exocrine Pancreatic Insufficiency (EPI) in Pediatric and Adult Participants With Alagille Syndrome After Liver Transplantation | Digestive Care, Inc. | Observational | Nashville |
| NCT07650032 | Cryoablation for Monomorphic Ventricular Tachycardia (VTS) | Adagio Medical | Device or behavioral (no phase) | Nashville |
| NCT07544979 | Creation of a Decision Aid for Coronary Anomalies | Vanderbilt University Medical Center | Device or behavioral (no phase) | Nashville |
| NCT07742735 | A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal F | VectivBio AG | Phase 3 | Nashville |
| NCT07686341 | PRecision Integrated Saturation Monitor | Le Bonheur Children's Hospital | Observational | Memphis |
| NCT07697456 | Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis | AbbVie | Phase 2 | Knoxville, Memphis |
| NCT07673367 | Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma | Vanderbilt-Ingram Cancer Center | Phase 2 | Nashville |
| NCT07441681 | Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin | NRG Oncology | Phase 3 | Nashville |
| NCT07857616 | SI-B036-ST-101 in Advanced/Metastatic Solid Tumors | SystImmune Inc. | Phase 1 | Nashville |
| NCT07616128 | Study of EVO756 in Adults With Migraine | Evommune, Inc. | Phase 2 | Franklin |
| NCT07659795 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer | Verastem, Inc. | Phase 2 | Nashville |
| NCT07681596 | A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma | AstraZeneca | Phase 1/2 | Nashville |
| NCT07585266 | A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal | GlaxoSmithKline | Phase 3 | Knoxville |
| NCT07497087 | A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis | Boehringer Ingelheim | Phase 3 | Jackson |
| NCT07830134 | Cognitive Rehabilitation for Survivors of Childhood Medulloblastoma Using Real Time Hemodynamic Neurofeedback | St. Jude Children's Research Hospital | Device or behavioral (no phase) | Memphis |
| NCT07675083 | Bereaved Parent Conversations on Hope | St. Jude Children's Research Hospital | Device or behavioral (no phase) | Memphis |
| NCT05996328 | CSP #2025 - Geriatric OUt-of-hospital Randomized MEal Trial in Heart Failure: Veterans Affairs (GOURMET-VA) | VA Office of Research and Development | Device or behavioral (no phase) | Nashville |
| NCT07755436 | Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometri | ArriVent BioPharma, Inc. | Phase 1 | Nashville |
| NCT07684235 | Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION) | Amgen | Phase 3 | Knoxville |
| NCT07383506 | A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors | Cogent Biosciences, Inc. | Phase 1 | Nashville |
| NCT07582861 | Prenatally-initiated Psychological Intervention for Mothers of Infants With Congenital Heart Disease (CHD) | Carelon Research | Device or behavioral (no phase) | Memphis |
| NCT07582848 | BOND: Direct Breastfeeding to Enhance Maternal and Infant Health in Congenital Heart Disease | Carelon Research | Device or behavioral (no phase) | Memphis |
| NCT07635563 | DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea. | Incannex Healthcare Ltd | Phase 2 | Memphis |
| NCT07232069 | PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis | Duke University | Phase 3 | Nashville |
| NCT07701694 | Functional Evaluation in Patients With Urea Cycle Disorders (UCD) During a Driving Task | St. Jude Children's Research Hospital | Observational | Memphis |
| NCT07382349 | A Study of Electronic Clinical Decision Support Tools for Steatotic Liver Disease | Vanderbilt University Medical Center | Device or behavioral (no phase) | Nashville |
| NCT07705035 | DBC-664 in Adult Patients With Solid Tumors | Duboce Biopharmaceuticals, Inc. | Phase 1 | Nashville |
| NCT07654374 | A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2) | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Phase 3 | Nashville |
| NCT07629206 | Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using ProSense® Cryoablation (ChoICE Trial) | IceCure Medical Ltd. | Device or behavioral (no phase) | Germantown |
| NCT07720284 | An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC | AstraZeneca | Phase 3 | Nashville |
| NCT07621809 | Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burde | Novartis Pharmaceuticals | Phase 3 | Jackson, Memphis |
| NCT07652242 | Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer | Immunomic Therapeutics, Inc. | Phase 1 | Nashville |
| NCT07466316 | A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients Wi | Children's Oncology Group | Phase 3 | Knoxville, Nashville |
| NCT07654361 | Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1) | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Phase 3 | Knoxville |
| NCT07696065 | Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials | Phoenix Children's Hospital | Early phase 1 | Memphis |
| NCT07673627 | ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Gen | argenx | Phase 2 | Chattanooga |
| NCT07544654 | DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With | Boehringer Ingelheim | Phase 3 | Knoxville, Nashville |
| NCT07318610 | Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease | Regeneron Pharmaceuticals | Phase 3 | Jackson, Knoxville, Tullahoma |
| NCT07260916 | Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation | Weill Medical College of Cornell University | Device or behavioral (no phase) | Nashville |
| NCT07663539 | Insights From Bereaved Parents and Oncologists | St. Jude Children's Research Hospital | Observational | Memphis |
| NCT07625280 | A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH | Jazz Pharmaceuticals | Phase 3 | Nashville |
| NCT07690436 | Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM | AstraZeneca | Observational | Germantown |
| NCT07668336 | A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes | Eli Lilly and Company | Phase 3 | Nashville |
| NCT07664553 | A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin | AstraZeneca | Phase 3 | Memphis |
| NCT07516951 | A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis | Chiesi Farmaceutici S.p.A. | Phase 2 | Hendersonville |
| NCT07314736 | Stakeholders of Rare Diseases Informing Values In Neuroethics | St. Jude Children's Research Hospital | Observational | Memphis |
| NCT07003295 | Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy | National Cancer Institute (NCI) | Phase 2 | Nashville |
| NCT07493447 | Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures | Eben Rosenthal | Early phase 1 | Nashville |
| NCT07492134 | APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis) | Vanderbilt University Medical Center | Phase 2 | Nashville |
| NCT07717879 | Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2) | Axsome Therapeutics, Inc. | Phase 3 | Memphis |
| NCT07662213 | A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat | AstraZeneca | Phase 3 | Memphis, Morristown |
| NCT07662109 | A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus | AstraZeneca | Phase 3 | Kingsport, Nashville |
| NCT07662044 | A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 | AstraZeneca | Phase 3 | Knoxville |
| NCT06957418 | Alzheimer's Tau Platform: Master Protocol | Paul S. Aisen | Phase 2 | Nashville |
| NCT07460765 | Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) | Vanderbilt-Ingram Cancer Center | Phase 1 | Nashville |
| NCT07499258 | Axonics R20 Post-Market Clinical Follow-up (PMCF) Study for the Indication of Fecal Incontinence | Axonics, Inc. | Observational | Nashville |
| NCT07365241 | A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory | AbbVie | Phase 3 | Knoxville, Memphis, Nashville |
| NCT07719361 | A Study in Patients With Metastatic Castration-Resistant Prostate Cancer | Flare Therapeutics Inc. | Phase 1 | Nashville |
| NCT07710300 | Randomized Controlled Trial Testing a Training Program About Section 504 of the Rehabilitation Act | Vanderbilt University | Device or behavioral (no phase) | Nashville |
| NCT07645924 | A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine | TriGemX Bio, Inc. | Phase 3 | Chattanooga, Nashville |
| NCT07609108 | Pridopidine Phase 3 Study in Huntington's Disease | Prilenia | Phase 3 | Nashville |
| NCT07559903 | ANDREAS Registry (Assessment of Novel Drug-coated Balloon Revascularization: Effectiveness, Angiographic Outcomes, and Safety) | Emory University | Observational | Nashville |
| NCT07426757 | An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers | Pfizer | Phase 1 | Nashville |
| NCT07172971 | Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy | Vanderbilt University Medical Center | Phase 1 | Nashville |
| NCT07095894 | A RCT of Spectacles With Aspherical Lenslets or 0.05% Atropine for Myopia Control | Jaeb Center for Health Research | Phase 3 | Nashville |
| NCT07751042 | Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab | Strand Therapeutics Inc. | Phase 1/2 | Nashville |
| NCT07747103 | An Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of North Star Desiccated Porcine Thyroid Extract Tablets. | Neuvosyn Laboratories, LLC | Phase 3 | Chattanooga |
| NCT07614984 | A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004) | Merck Sharp & Dohme LLC | Phase 2 | Kingsport |
| NCT07589634 | A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refract | Janssen Research & Development, LLC | Phase 2 | Nashville |
| NCT07489066 | Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC | Pfizer | Phase 2 | Knoxville |
| NCT07667803 | A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM | AstraZeneca | Phase 3 | Franklin, Knoxville |
| NCT07764978 | Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT | AstraZeneca | Phase 3 | Nashville |
| NCT07749170 | FORWARD: Functional Outcomes in Real-World Treatment And Revascularization of Non-dominant and Distal M2 Occlusions | Penumbra Inc. | Observational | Knoxville, Memphis |
| NCT07661056 | Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease | Biohaven Therapeutics Ltd. | Phase 3 | Chattanooga, Memphis |
| NCT07284602 | Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF) | PureTech | Phase 3 | Franklin, Knoxville |
| NCT07717892 | Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3) | Axsome Therapeutics, Inc. | Phase 3 | Memphis |
| NCT07621237 | A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD) | Tonix Pharmaceuticals, Inc. | Phase 2 | Mephis |
| NCT07357597 | An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Loca | AstraZeneca | Phase 4 | Knoxville |
| NCT07224672 | A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants Wi | GlaxoSmithKline | Phase 2 | Nashville |
| NCT07694440 | A Study of MZE782 in Adults With PKU | Maze Therapeutics | Phase 2 | Memphis |
| NCT07673107 | Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor | AbbVie | Phase 2 | Memphis |
| NCT07605429 | BEACON - Phase III Clinical Study of Rugonersen in Angelman Syndrome. | OHB Pediatrics Ltd. | Phase 3 | Nashville |
| NCT07511361 | Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension | Kardigan, Inc. | Phase 2 | Chattanooga |
| NCT07488923 | A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECT | Moonlight Bio, Inc | Phase 1 | Nashville |
| NCT07668388 | A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes | Novo Nordisk A/S | Phase 2 | Memphis |
| NCT07634471 | A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) | Merck Sharp & Dohme LLC | Phase 2/3 | Nashville |
| NCT07644052 | Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder | PleoPharma, Inc. | Phase 3 | Knoxville |
| NCT07728123 | Screen2Prevent (S2P) | Westat | Device or behavioral (no phase) | Memphis |
| NCT07644559 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer | Verastem, Inc. | Phase 2 | Nashville |
| NCT07502885 | Deep Phenotyping Gait Deficits in Orthopedic Manifestations of Pediatric Cancer Patients | St. Jude Children's Research Hospital | Observational | Memphis |
| NCT07456904 | Outcomes of Health Care Transition for AYA With a Cancer Predisposition | St. Jude Children's Research Hospital | Observational | Memphis |
| NCT07660198 | Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents | Pfizer | Phase 3 | Tullahoma |
| NCT07647328 | A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer | AstraZeneca | Phase 3 | Nashville |
| NCT07365319 | A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. | Eikon Therapeutics | Phase 2/3 | Nashville |
| NCT07220915 | Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections | Octapharma | Phase 3 | Murfreesboro |
| NCT07364162 | Exogenous Ketone Supplementation in ICU Delirium | Vanderbilt University Medical Center | Phase 2 | Nashville |
| NCT07012044 | A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Ch | National Cancer Institute (NCI) | Phase 1 | Memphis |
| NCT07504458 | Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia | Quetzal Therapeutics | Phase 3 | Nashville |
| NCT07222345 | Feasibility of High Intensity Interval Training in Survivors of Childhood, Adolescent, and Young Adult Hodgkin Lymphoma | St. Jude Children's Research Hospital | Device or behavioral (no phase) | Memphis |
| NCT07207993 | Evaluating Health Outcomes of AI-Based Fitness Wearables and App Programs in Older Adults Living Alone With Cognitive Decline | The University of Tennessee, Knoxville | Device or behavioral (no phase) | Knoxville |
| NCT07562152 | Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma | Immuneering Corporation | Phase 3 | Germantown, Nashville |
| NCT07448038 | A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With | Genentech, Inc. | Phase 2 | Nashville |
| NCT07383441 | Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer | SWOG Cancer Research Network | Phase 3 | Collierville, Memphis |
| NCT07675135 | A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy | Harmony Biosciences Management, Inc. | Phase 3 | Nashville |
| NCT07629960 | A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations | Blueprint Medicines Corporation | Phase 1/2 | Nashville |
| NCT07566286 | Study to Evaluate the Safety of Retreatment With Restylane® Lyft With Lidocaine for Augmentation of the Chin Region | Galderma R&D | Device or behavioral (no phase) | Nashville |
| NCT06824649 | Biologics in Chronic Rhinosinusitis With Nasal Polyposis | Medical University of South Carolina | Phase 4 | Nashville |
| NCT07392216 | Functional Ovarian Reserve in Sickle Cell Disease | St. Jude Children's Research Hospital | Observational | Memphis |
| NCT07518186 | A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma | Janssen Research & Development, LLC | Phase 3 | Nashville |
| NCT07629440 | A Study to Learn About How a New Pneumococcal Vaccine Works in Infants. | Pfizer | Phase 3 | Memphis, Tullahoma |
| NCT07607587 | Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events | Novo Nordisk A/S | Phase 1 | Bristol |
| NCT07607964 | A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adul | AbbVie | Phase 1 | Jackson |
| NCT07419841 | A Phase 1 Study of the Safety and Tolerability of CTX-10726 | Compass Therapeutics | Phase 1 | Nashville |
| NCT07101328 | A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) | Eli Lilly and Company | Phase 1 | Nashville |
| NCT07614776 | A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular D | Amgen | Phase 3 | Nashville |
| NCT07567040 | Delaying the Onset of Nearsightedness Until Treatment (DONUT) Clinical Trial | Ohio State University | Phase 3 | Memphis |
| NCT07542704 | A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies | Kumquat Biosciences Inc. | Phase 1 | Nashville |
| NCT07577856 | A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis | Janssen Research & Development, LLC | Phase 3 | Cordova |
| NCT07636590 | Multi-Center, Prospective, Non-Interventional Study in Subjects With Limbal Stem Cell Deficiency | Claris Biotherapeutics, Inc. | Observational | Smyrna |
| NCT07621718 | Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancre | Revolution Medicines, Inc. | Phase 3 | Nashville |
| NCT07577843 | A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease | Janssen Research & Development, LLC | Phase 3 | Cordova |
| NCT07492641 | BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment fo | BeOne Medicines | Phase 3 | Kingsport, Nashville |
| NCT07564414 | A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Los | Novo Nordisk A/S | Phase 3 | Jackson, Kingsport, Memphis, Morristown |
| NCT07531745 | ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome | Ionis Pharmaceuticals, Inc. | Phase 1/2 | Memphis |
| NCT07422480 | A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusion | Takeda | Phase 3 | Nashville |
| NCT07413939 | RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal | Hoffmann-La Roche | Phase 2/3 | Germantown, Nashville |
| NCT07633470 | A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE) | Alpha Cognition, Inc | Phase 4 | Cordova |
| NCT07306832 | A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute | AbbVie | Phase 1 | Nashville |
| NCT07228104 | Adjuvant Steroid Outcomes in Idiopathic Subglottic Stenosis | Johns Hopkins University | Phase 3 | Nashville |
| NCT07222514 | Feasibility and Safety of Single-Port Robotic-Assisted Deep Inferior Epigastric Pedicle Flap Harvest | Vanderbilt University Medical Center | Device or behavioral (no phase) | Nashville |
| NCT07646613 | Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhal | Aspeya, Inc. | Phase 2 | Memphis, Nashville |
| NCT07348601 | A Study of CSTI-500 in Patients With Prader-Willi Syndrome | ConSynance Therapeutics | Phase 2 | Nashville |
| NCT07392450 | A Study of TAK-755 in Adults With Acute Ischemic Stroke | Takeda | Phase 2 | Nashville |
| NCT07612644 | Hemorrhage Elimination During Lumbar Puncture Using Ultrasound Measurements (HELPUS) | Vanderbilt University Medical Center | Device or behavioral (no phase) | Nashville |
| NCT07599670 | A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease | AbbVie | Phase 1/2 | Cordova |
| NCT07589608 | A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight | Eli Lilly and Company | Phase 2 | Nashville |
| NCT07444580 | PrP-targeting siRNA Safety & Mechanism Study | Broad Institute of MIT and Harvard | Phase 1 | Nashville |
| NCT07227155 | The HOPE Biobank Resource (BMT CTN 2402 HOPE) | Medical College of Wisconsin | Observational | Nashville |
| NCT07225543 | 2-HOBA in Systemic Lupus Erythematosus | Vanderbilt University Medical Center | Phase 2 | Nashville |
| NCT07553429 | A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated | Boehringer Ingelheim | Phase 1/2 | Nashville |
| NCT07549503 | Early Signals of the Transition From Immune Quiescence to Activation in the Liver Allograft Microenvironment and in the Circulation | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | Nashville |
| NCT07387549 | A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis | Ipsen | Phase 3 | Cordova, Johnson City |
| NCT07277946 | AtraUmatic Laparoscopic HerNia Repair Clinical Investigation to Evaluate the Safety and Performance of The ECLIPSIUM System for Mesh Fixation IDE | Tissium | Device or behavioral (no phase) | Knoxville |
| NCT07142252 | Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 | Nashville |
| NCT07764133 | Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation and a Predictor of Treatment Response in Ovarian Cancer | University of Tennessee Graduate School of Medicine | Observational | Knoxville |
| NCT07572006 | A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies | Janssen Research & Development, LLC | Phase 1 | Nashville |
| NCT07287098 | A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early | Eli Lilly and Company | Phase 2 | Nashville |
| NCT06998940 | Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations | SWOG Cancer Research Network | Phase 3 | Collierville, Memphis |
| NCT06930755 | Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer | Nerviano Medical Sciences | Phase 1 | Nashville |
| NCT06465199 | Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas | Milton S. Hershey Medical Center | Phase 1/2 | Nashville |
| NCT07503886 | An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease | Dompé Farmaceutici S.p.A | Phase 2 | Memphis |
| NCT07286214 | Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica | Sanofi | Phase 3 | Jackson, Murfreesboro |
| NCT07567001 | A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity | Novo Nordisk A/S | Phase 3 | Greeneville, Jackson |
| NCT07566156 | Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309) | Astellas Pharma Global Development, Inc. | Phase 3 | Nashville |
| NCT07539311 | Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers | Genmab | Phase 2 | Nashville |
| NCT07441694 | Study of INCA036978 in Participants With Myeloproliferative Neoplasms | Incyte Corporation | Phase 1 | Nashville |
| NCT07436728 | A Study of TAK-505 in Adults With Solid Tumors | Takeda | Phase 1/2 | Nashville |
| NCT07214532 | Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer | Natera, Inc. | Device or behavioral (no phase) | Germantown, Nashville |
| NCT07610837 | Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis | AstraZeneca | Phase 2 | Clarksville |
| NCT07543120 | An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients. | Novartis Pharmaceuticals | Phase 2 | Memphis |
| NCT07549412 | A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metas | EMD Serono Research & Development Institute, Inc. | Phase 3 | Nashville |
| NCT07427394 | Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer | AstraZeneca | Phase 2 | Nashville |
| NCT07415031 | A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies | Mirati Therapeutics Inc. | Phase 2 | Germantown |
| NCT07568834 | Impact of Pelvic Pain Podcast | Vanderbilt University Medical Center | Device or behavioral (no phase) | Nashville |
| NCT07226453 | Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma | University of California, San Francisco | Phase 2 | Memphis |
| NCT07611110 | AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) | AstraZeneca | Phase 3 | Nashville |
| NCT07513376 | A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small | Merck Sharp & Dohme LLC | Phase 3 | Knoxville |
| NCT07519772 | A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) | Merck Sharp & Dohme LLC | Phase 1/2 | Nashville |
| NCT07625579 | Collaboration for Down Syndrome Progress (CDP) | RTI International | Observational | Memphis |
| NCT07607678 | A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimab | Boehringer Ingelheim | Phase 1 | Nashville |
| NCT07563829 | NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies | NextPoint Therapeutics, Inc. | Phase 1 | Nashville |
| NCT07435649 | Investigation of the Delve Detect Cerebrospinal Fluid (CSF) Metagenomic Next-generation Sequencing (mNGS) Test When Used for the Initial Diagnostic Workup of Pa | Delve Bio, Inc. | Device or behavioral (no phase) | Nashville |
| NCT06528691 | Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors | St. Jude Children's Research Hospital | Phase 2 | Memphis |
| NCT07521475 | Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes | Insulet Corporation | Device or behavioral (no phase) | Chattanooga |
| NCT07321652 | Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL | Alliance for Clinical Trials in Oncology | Phase 3 | Collierville, Memphis |
| NCT07053436 | Horizon Two: HR NDMM (MMRC-100) | Multiple Myeloma Research Consortium | Phase 2 | Nashville |
| NCT07567846 | A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer | Genentech, Inc. | Phase 1/2 | Nashville |
| NCT07469891 | A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms | Prelude Therapeutics Incorporated | Phase 1 | Nashville |
| NCT07293650 | PREcision MEDicine In Achalasia (PREMEDIA) | Northwestern University | Phase 3 | Nashville |
| NCT07188896 | A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC) | Brian Rini | Phase 2 | Nashville |
| NCT07493512 | Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer | Amgen | Phase 1 | Nashville |
| NCT07223437 | REVASC-PAD: REstricted VASCular Exercise for Peripheral Arterial Disease - A Feasibility Study at University of Tennessee Medical Center | University of Tennessee Graduate School of Medicine | Device or behavioral (no phase) | Knoxville |
| NCT07232030 | Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure | CVRx, Inc. | Device or behavioral (no phase) | Chattanooga, Germantown |
| NCT07217028 | Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma | Vanderbilt-Ingram Cancer Center | Phase 1 | Nashville |
| NCT07195734 | Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer | National Cancer Institute (NCI) | Phase 2 | Nashville |
| NCT07419295 | A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) | Merck Sharp & Dohme LLC | Phase 3 | Germantown, Knoxville, Nashville |
| NCT07365332 | An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH) | Inhibikase Therapeutics | Phase 3 | Nashville |
| NCT07228741 | Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity | St. Jude Children's Research Hospital | Phase 2 | Memphis |
| NCT07612189 | A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors | NEOK Bio, Inc. | Phase 1 | Nashville |
| NCT07611214 | PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis | Aurinia Pharmaceuticals Inc. | Phase 4 | Jackson |
| NCT07558733 | Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer | Faeth Therapeutics | Phase 1/2 | Nashville |
| NCT07365995 | A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer | BioNTech SE | Phase 3 | Nashville |
| NCT07612176 | A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors | NEOK Bio, Inc. | Phase 1 | Nashville |
| NCT07531095 | Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) | Amgen | Phase 1 | Memphis |
| NCT07425522 | A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME) | Genentech, Inc. | Phase 1 | Germantown |
| NCT07485647 | Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing | Eden Biltibo | Phase 2 | Nashville |
| NCT07409181 | A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE) | Boehringer Ingelheim | Phase 2 | Jackson, Memphis |
| NCT07085325 | CSIMEMPHIS: Long-term Follow-up of Medulloblastoma Survivors That Received Craniospinal Irradiation | St. Jude Children's Research Hospital | Observational | Memphis |
| NCT07415954 | A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes | Novo Nordisk A/S | Phase 2 | Memphis |
| NCT07226843 | A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers | Eli Lilly and Company | Phase 1 | Nashville |
| NCT07221214 | GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV | Vanderbilt University Medical Center | Phase 2 | Nashville |
| NCT07068074 | Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma | ECOG-ACRIN Cancer Research Group | Phase 3 | Nashville |
| NCT07058012 | A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal | NSABP Foundation Inc | Phase 2 | Kingsport |
| NCT07718347 | Post-market Cosmetic Evaluation of Ariessence™ Pure PDGF+ Following Ablative Laser | Lynch Regenerative Medicine | Device or behavioral (no phase) | Nashville |
| NCT07485244 | EEG Abnormalities in Adult ICU Patients With High Risk of Delirium | Ceribell Inc. | Observational | Nashville |
| NCT06828588 | Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy | Vanderbilt-Ingram Cancer Center | Early phase 1 | Nashville |
| NCT07545811 | Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer | Janux Therapeutics | Phase 1 | Nashville |
| NCT07513506 | Extensively Hydrolyzed Formula Growth Monitioring Study (GMS) | Mead Johnson Nutrition | Device or behavioral (no phase) | Memphis |
| NCT07496567 | A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) | EyeBiotech Ltd. | Phase 2/3 | Hixson, Johnson City, Knoxville, Nashville |
| NCT07227311 | A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myelo | GlaxoSmithKline | Phase 2 | Nashville |
| NCT07551791 | Suction vs Underwater Seal for HemoPneumoThoraX Trial | Vanderbilt University Medical Center | Device or behavioral (no phase) | Nashville |
| NCT07529691 | Survey on Physical Activity and Qualify of Life in Fibromuscular Dysplasia | Vanderbilt University Medical Center | Observational | Nashville |
| NCT07416123 | A Study of GEN1106 in Participants With Solid Tumors | Genmab | Phase 1 | Germantown |
| NCT06769698 | A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carci | Regeneron Pharmaceuticals | Phase 2 | Knoxville, Nashville |
| NCT07544589 | A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers | Dispatch Biotherapeutics | Phase 1 | Nashville |
| NCT07533175 | AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight | Novo Nordisk A/S | Phase 3 | Chattanooga |
| NCT07472517 | DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Stan | Boehringer Ingelheim | Phase 3 | Memphis |
| NCT07430306 | A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus | AstraZeneca | Phase 3 | Memphis |
| NCT07175441 | Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma | Riboscience, LLC. | Phase 2 | Nashville |
| NCT07563322 | Mechanistic Study of Nicotinamide Riboside on NAD+ Biology in Individuals With Combined Pulmonary Hypertension | Vanderbilt University Medical Center | Device or behavioral (no phase) | Nashville |
| NCT07524855 | A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer | Janssen Research & Development, LLC | Phase 1 | Nashville |
| NCT07522073 | A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma | Incyte Corporation | Phase 3 | Nashville |
| NCT07489495 | A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) | Merck Sharp & Dohme LLC | Phase 3 | Germantown |
| NCT07444216 | A Longitudinal Photo-Narrative Exploration of Hope During Phase 1/2 Clinical Trials For Pediatric Cancer | St. Jude Children's Research Hospital | Observational | Memphis |
| NCT07519655 | Phase 1 Study of PF-08046033 in Advanced Solid Tumors | Pfizer | Phase 1 | Nashville |
| NCT07519395 | A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel | GlaxoSmithKline | Phase 2 | Chattanooga, Johnson City, Kingsport, Knoxville |
| NCT07403721 | AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors | Amgen | Phase 1 | Nashville |
| NCT07298473 | Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation Syst | Medtronic Cardiac Ablation Solutions | Device or behavioral (no phase) | Nashville |
| NCT07843849 | Corticosteroid for Diabetic Macular Edema (DME) Study | Vanderbilt University Medical Center | Phase 4 | Nashville |
| NCT07424404 | A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolesc | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Phase 3 | Nashville |
| NCT07430956 | Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable | Regeneron Pharmaceuticals | Phase 3 | Tullahoma |
| NCT07540221 | A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Grifols Therapeutics LLC | Phase 3 | Cordova |
| NCT07456696 | An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1) | Transcend Therapeutics | Phase 3 | Memphis |
| NCT07556159 | A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice | Sanofi | Observational | Tennessee City |
| NCT07390318 | Bowel Continence Across the Lifespan in People With Spina Bifida | David Chu | Observational | Nashville |
| NCT07069413 | Sibwatch: Optimizing Intervention Options for Infants and Toddler Siblings of Autistic Children | University of Texas at Austin | Device or behavioral (no phase) | Nashville |
| NCT07586982 | Clinical Performance of Verofilcon A Toric Contact Lenses | Southern College of Optometry | Device or behavioral (no phase) | Memphis |
| NCT07551661 | Effects of an Independent Walking Program With Walking Poles in People With Parkinson Disease | East Tennessee State University | Device or behavioral (no phase) | Johnson City |
| NCT07462377 | A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC | EpiBiologics | Phase 1 | Nashville |
| NCT07439653 | A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma | TORL Biotherapeutics, LLC | Phase 1/2 | Nashville |
| NCT07191119 | Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic Leukemia | St. Jude Children's Research Hospital | Device or behavioral (no phase) | Memphis |
| NCT07440225 | A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) | EyeBiotech Ltd. | Phase 2/3 | Germantown |
| NCT07210632 | Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG) | Eben Rosenthal | Early phase 1 | Nashville |
| NCT07415044 | LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis | Eli Lilly and Company | Phase 2 | Jackson |
| NCT07144319 | Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy | Photocure | Observational | Nashville |
| NCT07491952 | Continuous Dual Aspiration Technique With Zoom System for Stroke | Imperative Care, Inc. | Observational | Knoxville, Memphis |
| NCT07326709 | A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease | Novartis Pharmaceuticals | Phase 3 | Memphis, Nashville |
| NCT07405164 | Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) | Merck Sharp & Dohme LLC | Phase 3 | Nashville |
| NCT07355296 | PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease | Boehringer Ingelheim | Phase 2 | Chattanooga |
| NCT07299019 | A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis | Zenas BioPharma (USA), LLC | Phase 3 | Cordova |
| NCT07067463 | A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis | Zenas BioPharma (USA), LLC | Phase 3 | Cordova |
| NCT07042295 | Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System | National Cancer Institute (NCI) | Phase 2 | Nashville |
| NCT07532603 | A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris | Priovant Therapeutics, Inc. | Phase 2/3 | Murfreesboro, Smyrna |
| NCT07390955 | A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | Nashville |
| NCT07300943 | Study in Advanced Solid Tumor Patients | Callio Therapeutics | Phase 1/2 | Nashville |
| NCT07154290 | A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | Regeneron Pharmaceuticals | Phase 2 | Knoxville, Nashville |
| NCT07473778 | Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention | Gilead Sciences | Observational | Nashville |
| NCT07387367 | A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT | SymBio Pharmaceuticals | Phase 3 | Memphis |
| NCT07500090 | A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH) | Harmony Biosciences Management, Inc. | Phase 3 | Nashville |
| NCT07482176 | Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS) | Adverum Biotechnologies, Inc. | Phase 3 | Nashville |
| NCT07467980 | Endoscopic COlorectal Mucosal Evaluation of Oxygen Tension | Vanderbilt University Medical Center | Observational | Nashville |
| NCT07361497 | A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Canc | Bristol-Myers Squibb | Phase 3 | Nashville |
| NCT07351045 | A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes | Hoffmann-La Roche | Phase 3 | Clarksville, Nashville |
| NCT07291076 | A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable He | Bristol-Myers Squibb | Phase 1/2 | Nashville |
| NCT07143019 | The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms | phenox Inc. | Device or behavioral (no phase) | Nashville |
| NCT07221149 | A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With | Bristol-Myers Squibb | Phase 2/3 | Nashville |
| NCT07491497 | A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC | TRIANA Biomedicines, Inc. | Phase 1/2 | Nashville |
| NCT07421700 | Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer | Pfizer | Phase 1/2 | Chattanooga, Cookeville, Dickson, Franklin |
| NCT07339111 | Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis | Medipost, Inc. | Phase 3 | Jackson |
| NCT07286058 | Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis | Takeda | Phase 3 | Jackson |
| NCT07584226 | A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors | Relay Therapeutics, Inc. | Phase 1/2 | Nashville |
| NCT07491445 | Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma | Revolution Medicines, Inc. | Phase 3 | Nashville |
| NCT07431177 | A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo | Novartis Pharmaceuticals | Phase 2 | Murfreesboro |
| NCT07438496 | A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus | Janssen Research & Development, LLC | Phase 3 | Jackson |
| NCT07284849 | A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic | Incyte Corporation | Phase 3 | Knoxville |
| NCT07277413 | A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors | IDEAYA Biosciences | Phase 1 | Nashville |
| NCT07221838 | A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab | Alexion Pharmaceuticals, Inc. | Phase 4 | Knoxville |
| NCT07422376 | Evaluation of Scalp Cooling During Chemotherapy on Quality of Life and the Potential Role of Single Nucleotide Variations on Chemotherapy-Induced Alopecia and H | Charles Mays | Device or behavioral (no phase) | Kingsport |
| NCT07325526 | A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH) | Boehringer Ingelheim | Phase 2 | Nashville |
| NCT06738407 | Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections | Westat | Phase 4 | Memphis |
| NCT07379827 | Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) | Bristol-Myers Squibb | Observational | Cordova, Franklin, Nashville |
| NCT07432958 | A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations | Appello Pharmaceuticals, Inc. | Phase 2 | Nashville |
| NCT07503808 | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types | IDEAYA Biosciences | Phase 1 | Nashville |
| NCT07406997 | Rehabilitation With Empowered STrategies to Optimize REcovery | Vanderbilt University Medical Center | Device or behavioral (no phase) | Nashville |
| NCT07293559 | Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | Observational | Memphis |
| NCT07224425 | A Study of BI 3810944 in Patients With Advanced Cancer | Boehringer Ingelheim | Phase 1 | Nashville |
| NCT06875960 | A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Ery | Bristol-Myers Squibb | Phase 4 | Jackson |
| NCT07484217 | Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol | Axsome Therapeutics, Inc. | Phase 3 | Memphis |
| NCT07391657 | A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refra | AstraZeneca | Phase 3 | Nashville |
| NCT07079358 | Improving Veteran Referral to Cardiac Rehabilitation | VA Office of Research and Development | Device or behavioral (no phase) | Nashville |
| NCT06900595 | Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortica | National Cancer Institute (NCI) | Phase 2 | Memphis |
| NCT06842498 | A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Kyntra Bio | Phase 2 | Nashville |
| NCT07817147 | CREO - Microwave Ablation Feasibility Study | Banner Health | Device or behavioral (no phase) | Knoxville |
| NCT07686211 | Deformable Tissue Modelling and Augmented Reality Based Guidance for Head and Neck Tumor Re-Resection Task | Vanderbilt University Medical Center | Early phase 1 | Nashville |
| NCT07428447 | Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease | CND Life Sciences | Observational | Memphis, Nashville |
| NCT07284758 | A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | C4 Therapeutics, Inc. | Phase 2 | Nashville |
| NCT07335497 | CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors | Crescent Biopharma, Inc. | Phase 1/2 | Nashville |
| NCT05361733 | A First in Human Study of the Safety, Tolerability, and the Physiologically Based Pharmacokinetics of XFB19 in Healthy Adult Volunteers. | Xfibra, Inc. | Phase 1 | Knoxville |
| NCT07465432 | Pharmacokinetic Analysis of Cefiderocol in Patients With Acute Burn Injuries | University of Tennessee | Phase 4 | Memphis |
| NCT07318558 | A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) | Merck Sharp & Dohme LLC | Phase 3 | Germantown, Knoxville, Nashville |
| NCT07220083 | A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS) | Boehringer Ingelheim | Phase 3 | Chattanooga |
| NCT07156318 | Drumming Lessons' Influence on Children With Down Syndrome | Vanderbilt University | Device or behavioral (no phase) | Nashville |
| NCT07491458 | A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis ( | Rivus Pharmaceuticals, Inc. | Phase 2 | Clarksville |
| NCT07283939 | Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays | Alliance for Clinical Trials in Oncology | Device or behavioral (no phase) | Collierville, Memphis |
| NCT07210723 | A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy | Kardigan, Inc. | Phase 2/3 | Nashville |
| NCT07059091 | Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD | Johns Hopkins University | Phase 2 | Nashville |
| NCT07363694 | A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease | Pfizer | Phase 2/3 | Franklin, Hendersonville |
| NCT07197944 | Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS | Zealand Pharma | Phase 3 | Nashville |
| NCT07227415 | Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Ad | Pfizer | Phase 1/2 | Chattanooga, Cookeville, Dickson, Franklin |
| NCT07201922 | A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis | Boehringer Ingelheim | Phase 3 | Nashville |
| NCT07455136 | A Study to Develop a Blood-based Test for Aiding the Diagnosis/Prognosis of Traumatic Brain Injury in Adults and for Monitoring the Development of Secondary Eve | Hoffmann-La Roche | Observational | Nashville |
| NCT07388498 | A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intrave | Amgen | Phase 3 | Jackson |
| NCT07321886 | A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes | Eli Lilly and Company | Phase 3 | Nashville |
| NCT07213830 | A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advan | Ipsen | Phase 1/2 | Nashville |
| NCT07304089 | A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia | Vima Therapeutics | Phase 2 | Memphis, Nashville |
| NCT07287995 | A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors | Astellas Pharma Global Development, Inc. | Phase 1/2 | Nashville |
| NCT07194044 | Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 | Nashville |
| NCT07372625 | A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients Wi | PMV Pharmaceuticals, Inc | Phase 1 | Nashville |
| NCT07370584 | A Safety Study of IVMED-85 Ophthalmic Solution in Healthy Adults | iVeena Delivery Systems, Inc. | Phase 1 | Memphis |
| NCT07258511 | A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma | Janssen Research & Development, LLC | Phase 3 | Nashville |
| NCT07214597 | NICU Utilization of Remote Voice Technology to Improve mateRnal Experience (NURTURE) | Vanderbilt University Medical Center | Device or behavioral (no phase) | Nashville |
| NCT07431281 | Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junctio | AstraZeneca | Phase 3 | Memphis, Nashville |
| NCT07333547 | Registry Study for the Evaluation of High-risk Cardiac Patients by WILLEM AI-based ECG Platform | Idoven 1903 S.L. | Observational | Nashville |
| NCT07325136 | A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer | Bristol-Myers Squibb | Phase 1/2 | Nashville |
| NCT07223203 | TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy | Alnylam Pharmaceuticals | Phase 3 | Nashville |
| NCT05437562 | Randomized Clinical Trial for Ewing Amputation in the VA | VA Office of Research and Development | Device or behavioral (no phase) | Nashville |
| NCT07397338 | Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors | Revolution Medicines, Inc. | Phase 1/2 | Nashville |
| NCT07307664 | Increasing Germline Genetic Testing for Patients With Cancer | Josh Peterson | Device or behavioral (no phase) | Nashville |
| NCT07288177 | Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer | Genmab | Phase 2 | Nashville |
| NCT07428538 | Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH) | Bausch Health Americas, Inc. | Phase 3 | Chattanooga, Nashville |
| NCT07312903 | DPTX3186 in Wnt Pathway Activated Solid Tumors | Dewpoint Therapeutics | Phase 1 | Boston |
| NCT07288567 | A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN) | Bristol-Myers Squibb | Phase 3 | Nashville |
| NCT07227597 | A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) | Merck Sharp & Dohme LLC | Phase 1/2 | Knoxville, Memphis, Nashville |
| NCT07121946 | This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma | LTZ Therapeutics, Inc. | Phase 1 | Nashville |
| NCT06651177 | Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder | T. John Winhusen, PhD | Phase 2 | Nashville |
| NCT07323654 | A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma | Kymera Therapeutics, Inc. | Phase 2 | Chattanooga |
| NCT07259317 | Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma | Corcept Therapeutics | Phase 2 | Nashville |
| NCT07198074 | Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, | National Cancer Institute (NCI) | Phase 3 | Franklin, Nashville |
| NCT07287917 | Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors | Aminex Therapeutics, Inc. | Phase 1/2 | Nashville |
| NCT07015190 | Neoadjuvant Darovasertib in Primary Uveal Melanoma | IDEAYA Biosciences | Phase 3 | Nashville |
| NCT07244211 | MAPT Protocol: Fixation Versus Arthroplasty Surgical Treatments for Early Recovery After HIP Fracture (FASTER-HIP) | University of Southern California | Device or behavioral (no phase) | Nashville |
| NCT07222735 | Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas | St. Jude Children's Research Hospital | Phase 1 | Memphis |
| NCT07658222 | Prospective Investigation of Cirrhotic Cardiomyopathy in Humans | Vanderbilt University Medical Center | Observational | Nashville |
| NCT06625073 | Randomized Trial of SGLT2i in Heart Transplant Recipients | VA Office of Research and Development | Phase 4 | Nashville |
| NCT06579469 | Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy | St. Jude Children's Research Hospital | Observational | Memphis |
| NCT07216703 | A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-287 | Merck Sharp & Dohme LLC | Phase 3 | Knoxville |
| NCT07196462 | Precision Brain Stimulation to Reduce Cannabis Craving in Schizophrenia | Vanderbilt University Medical Center | Device or behavioral (no phase) | Nashville |
| NCT07195682 | A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) | Bristol-Myers Squibb | Phase 1 | Nashville |
| NCT06837480 | Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema | Abramson Cancer Center at Penn Medicine | Device or behavioral (no phase) | Nashville |
| NCT06701812 | Digoxin Medulloblastoma Study | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 | Nashville |
| NCT07398417 | Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design | Axsome Therapeutics, Inc. | Phase 3 | Knoxville, Memphis |
| NCT07325292 | Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis | Sanofi | Phase 3 | Knoxville |
| NCT07382167 | A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults | Ardelyx | Phase 3 | Bristol, Hendersonville, Knoxville, Memphis |
| NCT06919224 | Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease | Ohio State University | Device or behavioral (no phase) | Nashville |
| NCT07188558 | A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy | Lyell Immunopharma, Inc. | Phase 3 | Nashville |
| NCT07358078 | DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting | Alnylam Pharmaceuticals | Observational | Memphis |
| NCT07284784 | A Study of Buntanetap in Participants With PD | Annovis Bio Inc. | Phase 2/3 | Cordova, Memphis |
| NCT07271186 | Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease | Regeneron Pharmaceuticals | Phase 2 | Chattanooga |
| NCT05723926 | Carotid Implants for PreveNtion of STrokE ReCurrEnce From Large Vessel Occlusion in Atrial Fibrillation Patients Treated With Oral Anticoagulation | Javelin Medical | Device or behavioral (no phase) | Chattanooga, Memphis |
| NCT07253285 | A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight | Novo Nordisk A/S | Phase 3 | Memphis |
| NCT07195916 | A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies | Incyte Corporation | Phase 1 | Nashville |
| NCT07095452 | A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, | AbbVie | Phase 2/3 | Nashville |
| NCT07135895 | The ArtixASCEND Study | Inari Medical | Device or behavioral (no phase) | Nashville |
| NCT07284433 | Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies | AvenCell Therapeutics, Inc. | Phase 1/2 | Nashville |
| NCT07222566 | Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or | Pfizer | Phase 3 | Chattanooga, Franklin, Gallatin, Knoxville |
| NCT07219043 | A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation | Biogen | Phase 2 | Nashville |
| NCT07217587 | Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis | Janssen Research & Development, LLC | Phase 3 | Cordova |
| NCT07115329 | A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder | Syndeio Biosciences, Inc | Phase 2 | Franklin |
| NCT06517693 | Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | Memphis |
| NCT07063745 | A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First | Bristol-Myers Squibb | Phase 2/3 | Knoxville |
| NCT07457489 | Vanderbilt Integrated Community TMS for Opioid Recovery | Vanderbilt University Medical Center | Device or behavioral (no phase) | Brentwood, Nashville |
| NCT07376005 | Effects of Acute Sugar Intake on Choroidal Thickness | Southern College of Optometry | Device or behavioral (no phase) | Memphis |
| NCT07221357 | A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants Wi | Bristol-Myers Squibb | Phase 2/3 | Nashville |
| NCT07361562 | A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors | Cogent Biosciences, Inc. | Phase 1 | Nashville |
| NCT07335601 | Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH | Madrigal Pharmaceuticals, Inc. | Phase 2 | Nashville |
| NCT07288359 | Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | Novartis Pharmaceuticals | Phase 1/2 | Nashville |
| NCT07218809 | AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer | AstraZeneca | Phase 3 | Germantown |
| NCT07254806 | A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disea | DiscGenics, Inc. | Phase 3 | Memphis |
| NCT07265947 | Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma | Tyra Biosciences, Inc | Phase 2 | Nashville |
| NCT07174336 | A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) | Eli Lilly and Company | Phase 3 | Nashville |
| NCT07294170 | ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis | argenx | Observational | Chattanooga |
| NCT07284420 | ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthe | argenx | Phase 2 | Chattanooga |
| NCT07225946 | A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer | Janssen Research & Development, LLC | Phase 3 | Knoxville |
| NCT07276997 | A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder | AbbVie | Phase 2 | Memphis |
| NCT07189936 | Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS | Vanderbilt University Medical Center | Phase 2 | Nashville |
| NCT06939803 | AI-driven Clinical Decision Support to Reduce Hospital-Acquired Venous Thromboembolism: Study Protocol for the VTE-AI Randomized Trial. | Vanderbilt University Medical Center | Device or behavioral (no phase) | Nashville |
| NCT07239336 | Study of DONQ52 in Active Celiac Disease | Chugai Pharmaceutical | Phase 2 | Hermitage |
| NCT06686771 | Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer | Canadian Cancer Trials Group | Phase 3 | Nashville |
| NCT07373639 | A Long-term Follow-up Study in Patients Who Received BEAM-101 | Beam Therapeutics Inc. | Observational | Memphis, Nashville |
| NCT07252232 | Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) | Revolution Medicines, Inc. | Phase 3 | Nashville |
| NCT07219407 | A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures | Rapport Therapeutics Inc. | Phase 2 | Nashville |
| NCT06200259 | Reduction of Gastrointestinal Toxicity in Prostate Cancer by Proton Spot Placement | Covenant Health Cancer Center | Device or behavioral (no phase) | Knoxville |
| NCT07221474 | A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) | Merck Sharp & Dohme LLC | Phase 2 | Nashville |
| NCT07221188 | A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH | GlaxoSmithKline | Phase 3 | Chattanooga |
| NCT07218380 | A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract | Eli Lilly and Company | Phase 3 | Nashville |
| NCT07062588 | Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN) | Angitia Incorporated Limited | Phase 2 | Nashville |
| NCT06604884 | NV PSR INSPIRE-A Pipeline™ Vantage Post Approval Study | Medtronic Neurovascular Clinical Affairs | Observational | Memphis |
| NCT07222800 | Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal | Pfizer | Phase 3 | Nashville |
| NCT07565727 | Cardiometabolic Disease and Substrate Metabolism | University of Tennessee Graduate School of Medicine | Observational | Knoxville |
| NCT07290036 | A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults | UCB Biopharma SRL | Phase 1 | Jackson, Murfreesboro |
| NCT07285213 | Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody | AstraZeneca | Phase 2 | Johnson City |
| NCT07282665 | A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older | Pfizer | Phase 3 | Knoxville, Memphis, Nashville |
| NCT07155187 | A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Co | AbbVie | Phase 2/3 | Knoxville, Nashville |
| NCT07323784 | A Study of NTX-1472 in Social Anxiety Disorder | Newleos Therapeutics, Inc. | Phase 2 | Memphis |
| NCT07216443 | Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | Orca Biosystems, Inc. | Phase 2 | Nashville |
| NCT07214779 | Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | Incyte Corporation | Phase 3 | Chattanooga |
| NCT07221253 | A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) | AstraZeneca | Phase 3 | Nashville |
| NCT07277270 | A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors | GlaxoSmithKline | Phase 1 | Nashville |
| NCT07276399 | A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer | Janssen Research & Development, LLC | Phase 3 | Knoxville, Nashville |
| NCT07268638 | A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS) | Akebia Therapeutics | Phase 2 | Chattanooga |
| NCT07218926 | A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy | GlaxoSmithKline | Phase 3 | Knoxville |
| NCT07165132 | Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. | RayzeBio, Inc. | Phase 1 | Nashville |
| NCT06979453 | A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis | Bristol-Myers Squibb | Phase 3 | Goodlettsville, Nashville |
| NCT07395232 | An Efficacy and Safety Study of DFL24498 in the Treatment of AKC | Dompé Farmaceutici S.p.A | Phase 3 | Memphis |
| NCT07224243 | Impact of Intraoperative Oxygenation Practices on Patient Outcomes | Frederic T Billings IV | Device or behavioral (no phase) | Nashville |
| NCT07196644 | A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That H | AbbVie | Phase 2 | Nashville |
| NCT07218146 | A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) | Zai Lab (Shanghai) Co., Ltd. | Phase 3 | Nashville |
| NCT07144852 | Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities | Sun Pharmaceutical Industries, Inc. | Phase 3 | Knoxville, Nashville |
| NCT07213674 | A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer | Amgen | Phase 3 | Nashville |
| NCT07236099 | Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 2 | Murfreesboro |
| NCT07233239 | A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures | Jazz Pharmaceuticals | Phase 1 | Memphis |
| NCT07227402 | A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033) | Merck Sharp & Dohme LLC | Phase 3 | Knoxville |
| NCT07217301 | A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer | Takeda | Phase 3 | Knoxville |
| NCT07226219 | Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease | St. Jude Children's Research Hospital | Phase 1 | Memphis |
| NCT07225751 | A Prospective, Randomized, Single-blind, Controlled, Multi-center Study to Assess the Safety and Performance of MagnetOsTM Compared to Autogenous Bone Graft in | Kuros Biosurgery AG | Device or behavioral (no phase) | Chattanooga |
| NCT07214012 | Planning Together: A Couple-based, Multi-level Prenatal Contraceptive Education Program for Economically Marginalized Families | University of Tennessee Graduate School of Medicine | Device or behavioral (no phase) | Knoxville |
| NCT07176650 | Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) | Shanghai Henlius Biotech | Phase 1 | Brentwood |
| NCT07061964 | Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial | National Cancer Institute (NCI) | Phase 2 | Germantown |
| NCT07174310 | A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease | Hoffmann-La Roche | Phase 3 | Memphis, Nashville |
| NCT07231419 | Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy | Vertex Pharmaceuticals Incorporated | Phase 3 | Chattanooga, Kingsport, Knoxville, Memphis |
| NCT06971939 | Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants | Neurotech Pharmaceuticals | Phase 4 | Knoxville |
| NCT07136181 | Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma | Novelwise Pharmaceutical Corporation | Phase 1/2 | Nashville |
| NCT07205718 | A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors | Takeda | Phase 1/2 | Nashville |
| NCT07144345 | Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp | Sun Pharmaceutical Industries, Inc. | Phase 3 | Nashville |
| NCT07228832 | Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer | Summit Therapeutics | Phase 3 | Germantown, Hermitage |
| NCT07192432 | Gene Therapy for HER-Positive Cancer (SENTRY-HER2) | Vironexis Biotherapeutics Inc. | Phase 1/2 | Nashville |
| NCT07116434 | Discovery Diabetes | Vanderbilt University Medical Center | Device or behavioral (no phase) | Nashville |
| NCT07217171 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas | EvolveImmune United, Inc | Phase 1 | Nashville |
| NCT07059845 | A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participa | AbbVie | Phase 2 | Knoxville |
| NCT07109219 | Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia | AstraZeneca | Phase 1/2 | Franklin |
| NCT07225504 | A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis | Novartis Pharmaceuticals | Phase 3 | Cordova, Nashville |
| NCT07186101 | LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis: | Eli Lilly and Company | Phase 2 | Cordova |
| NCT07085338 | A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neurob | St. Jude Children's Research Hospital | Phase 2 | Memphis |
| NCT06798298 | A Safety and Efficacy Long-Term Follow-up Study of Adult Participants Treated With Gene Modified T Cells | Regeneron Pharmaceuticals | Observational | Nashville |
| NCT07110246 | Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas | University of California, San Francisco | Phase 2 | Memphis |
| NCT07206225 | A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer | Pfizer | Phase 1 | Nashville |
| NCT07015242 | A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous Sys | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Phase 2 | Nashville |
| NCT07100080 | Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGH | Bristol-Myers Squibb | Phase 2/3 | Chattanooga, Nashville |
| NCT07225127 | Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2 | University of Washington | Observational | Nashville |
| NCT07085767 | Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer | Olema Pharmaceuticals, Inc. | Phase 3 | Bartlett, Knoxville, Mount Juliet, Nashville |
| NCT07266948 | Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work | Southern College of Optometry | Phase 4 | Memphis |
| NCT07112924 | CCM OPEN HF Registry | Impulse Dynamics | Observational | Germantown |
| NCT05213676 | De-implementing Inhaled Nitric Oxide for Congenital Diaphragmatic Hernia | The University of Texas Health Science Center, Houston | Phase 4 | Memphis, Nashville |
| NCT06699121 | A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC | LISCure Biosciences | Phase 2 | Nashville |
| NCT07291037 | Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Gen | AstraZeneca | Phase 3 | Memphis |
| NCT07223593 | Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease | Eli Lilly and Company | Phase 3 | Jackson, Jefferson City |
| NCT07201051 | A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis | GlaxoSmithKline | Phase 2 | Franklin, Knoxville |
| NCT07182149 | A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors | Normunity AccelCo, Inc. | Phase 1 | Nashville |
| NCT07173751 | ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer | BioNTech SE | Phase 3 | Germantown, Nashville |
| NCT07146516 | Retinal Detachment Prevention (Laser Prophylaxis) in Stickler Syndrome (SS) | Helen Keller Eye Research Foundation | Device or behavioral (no phase) | Nashville |
| NCT06532474 | Exploring the Physiologic, Pharmacodynamic, and Clinical Responses of Skeletal Muscle in Patients With Spinal Muscular Atrophy Treated With SMN-Directed Therapi | St. Jude Children's Research Hospital | Observational | Memphis |
| NCT06939751 | OPtimal Adult Heart Transplant Immunosuppression With MicroRNA Levels | Northwestern University | Observational | Nashville |
| NCT06934967 | Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients | Novartis Pharmaceuticals | Phase 3 | Memphis |
| NCT06701656 | JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab | PPD Development, LP | Phase 2 | Nashville |
| NCT06659445 | Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD | ONL Therapeutics | Phase 2 | Nashville |
| NCT07211178 | Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies | Tempus AI | Observational | Nashville |
| NCT06992258 | A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer | Criterium, Inc. | Phase 2 | Nashville |
| NCT07221227 | A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH | GlaxoSmithKline | Phase 3 | Chattanooga |
| NCT07048535 | CAR T-cell Long-Term Follow-Up, Quality of Life and Adverse Reactions | St. Jude Children's Research Hospital | Observational | Memphis |
| NCT07001748 | Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Ca | ECOG-ACRIN Cancer Research Group | Phase 2/3 | Nashville |
| NCT06989775 | BoxX-NoAF Clinical Trial | AtriCure, Inc. | Device or behavioral (no phase) | Nashville |
| NCT06793215 | A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With | Hoffmann-La Roche | Phase 3 | Memphis |
| NCT07220408 | Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis | Telios Pharma, Inc. | Phase 2 | Smyrna |
| NCT07220811 | Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy | RAPT Therapeutics, Inc., a member of the GSK plc group of companies | Phase 2 | Nashville |
| NCT07219173 | A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma | Eli Lilly and Company | Phase 2 | Nashville |
| NCT07213804 | A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer | Eli Lilly and Company | Phase 3 | Nashville |
| NCT07069738 | Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure | Boston Scientific Corporation | Device or behavioral (no phase) | Nashville |
| NCT07027514 | A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer | Ankyra Therapeutics, Inc | Phase 1 | Nashville |
| NCT07213609 | A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors | GlaxoSmithKline | Phase 1/2 | Nashville |
| NCT07177339 | eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation | GlaxoSmithKline | Phase 3 | Knoxville |
| NCT07175428 | Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation | Regeneron Pharmaceuticals | Phase 2 | Jefferson City |
| NCT07045194 | Virtue® SAB in the Treatment of Coronary ISR Trial | Orchestra BioMed, Inc | Device or behavioral (no phase) | Nashville |
| NCT06971731 | A Study of JNT-517 in Participants With Phenylketonuria (PKU) | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 | Nashville |
| NCT07229430 | Safety and Effectiveness Evaluation of the High-intensity Focused Ultrasound Device for Lifting Lax Submental and Neck Tissue | CLASSYS Inc. | Device or behavioral (no phase) | Nashville |
| NCT07221500 | A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) | Nurix Therapeutics, Inc. | Phase 2 | Nashville |
| NCT07165028 | A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Eli Lilly and Company | Phase 3 | Chattanooga, Cordova |
| NCT06800963 | ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG | ImmunityBio, Inc. | Phase 1/2 | Germantown, Nashville |
| NCT07174583 | A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer | IDEAYA Biosciences | Phase 1/2 | Nashville |
| NCT06934356 | Subcortical Arousal in Perceptual Awareness | Yale University | Device or behavioral (no phase) | Nashville |
| NCT06482944 | Whole Food for Families: A Pilot RCT of a Dietary Guidelines-Based Intervention to Prevent Type 2 Diabetes | Vanderbilt University | Device or behavioral (no phase) | Nashville |
| NCT07184996 | An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis | Sanofi | Phase 3 | Cordova |
| NCT07175285 | A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants | Bristol-Myers Squibb | Observational | Murfreesboro |
| NCT07140900 | Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic | Amgen | Phase 1 | Nashville |
| NCT07100106 | A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced | Genentech, Inc. | Phase 1/2 | Mount Juliet, Nashville |
| NCT07097142 | Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER | NRG Oncology | Phase 3 | Nashville |
| NCT07070219 | A Study of CTD402 in T-ALL/LBL Patients | Imviva Bio | Phase 1/2 | Nashville |
| NCT06613568 | Moda-flx Hemodialysis System™ Under Professional Care Settings by Trained Individuals and At Home by Participants | Diality Inc. | Device or behavioral (no phase) | Knoxville |
| NCT07205068 | Improved Outcomes With Pre-Procedure Shockwave IVL of Common Femoral Artery Access Site Prior to Large Bore Access and Pre-Closure | University of Tennessee Graduate School of Medicine | Device or behavioral (no phase) | Knoxville |
| NCT07142304 | The Lilac Device Trial - IMPACT: A Clinical Investigation on IMproving Peripheral Neuropathy Induced by Chemotherapy With Advanced Compression Technology - A Sa | Luminate Medical, Inc. | Device or behavioral (no phase) | Nashville |
| NCT06989437 | A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue | Pfizer | Phase 2/3 | Nashville |
| NCT07207811 | CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyret | Novo Nordisk A/S | Phase 3 | Nashville |
| NCT07193511 | BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors | Avenzo Therapeutics, Inc. | Phase 1/2 | Nashville |
| NCT07184931 | An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease | Sanofi | Phase 3 | Cordova, Kingsport |
| NCT07041099 | A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease | Cullinan Therapeutics Inc. | Phase 1 | Memphis |
| NCT06930976 | Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells | Vanderbilt University Medical Center | Device or behavioral (no phase) | Nashville |
| NCT06745908 | Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced o | ImmunityBio, Inc. | Phase 3 | Nashville |
| NCT07179055 | An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye | Vanda Pharmaceuticals | Phase 2 | Memphis |
| NCT07116616 | A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma | ModernaTX, Inc. | Phase 1/2 | Nashville |
| NCT07106762 | Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy | Bristol-Myers Squibb | Phase 2/3 | Nashville |
| NCT07204340 | TLN-372 in Advanced KRAS Mutant Solid Tumors | Treeline Biosciences, Inc. | Phase 1 | Nashville |
| NCT07144280 | A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Liga | Pfizer | Phase 3 | Bartlett, Chattanooga, Cleveland, Collierville |
| NCT07011576 | A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL) | SCRI Development Innovations, LLC | Phase 2 | Nashville |
| NCT07028853 | This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide | Pfizer | Phase 3 | Chattanooga, Cleveland, Cookeville, Dickson |
| NCT07133633 | A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013) | Merck Sharp & Dohme LLC | Phase 2 | Murfreesboro |
| NCT07129993 | Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastat | Daiichi Sankyo | Phase 2/3 | Germantown, Memphis, Nashville |
| NCT07007312 | Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML | Kura Oncology, Inc. | Phase 3 | Memphis, Nashville |
| NCT06877793 | Real-Time Diagnosis of Life-Threatening Necrotizing Soft Tissue Infections (NSTI) Using Indocyanine Green (ICG) Kinetic Modeling | Eric R. Henderson | Observational | Nashville |
| NCT07159763 | A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06) | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 3 | Hendersonville |
| NCT07052370 | TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoieti | St. Jude Children's Research Hospital | Phase 1 | Memphis |
Recruiting trials are studies on ClinicalTrials.gov with an overall status of Recruiting and at least one location in Tennessee, pulled in full from the ClinicalTrials.gov API v2. The national figure is every study with an overall status of Recruiting. Disease areas use the MeSH categories ClinicalTrials.gov assigns to each study's conditions. Phase 1/2 and phase 2/3 trials are shown as their own groups. The searchable table shows the 650 trials with the most recent start dates to keep the page light; the full list is on ClinicalTrials.gov.
The AI list comes from two ClinicalTrials.gov searches (AI and machine learning terms, and "AI" in titles, keywords and interventions) across Tennessee studies of every status, then a text check that drops studies where the terms only appear in long descriptions or mean something else, such as "aromatase inhibitor (AI)". It is a keyword count, so it can miss studies that use AI without saying so in those fields.
A listing on ClinicalTrials.gov is self-reported by the sponsor. A study can show as recruiting overall while an individual Tennessee site has paused or closed enrollment.
Source: US National Library of Medicine, ClinicalTrials.gov, API v2, data of November 4, 2026. Retrieved November 4, 2026. Checked daily. Download the data (JSON).
Running trials or selling into research operations in Tennessee? Our Expert Advisors know the research offices and how studies get started.